X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7803) 7803
Newsletter (354) 354
Magazine Article (60) 60
Book Chapter (11) 11
Newspaper Article (9) 9
Dissertation (6) 6
Publication (3) 3
Book / eBook (1) 1
Book Review (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
simvastatin (5979) 5979
humans (4152) 4152
male (3098) 3098
pharmacology & pharmacy (2839) 2839
animals (2659) 2659
statins (2598) 2598
simvastatin - pharmacology (2564) 2564
female (2118) 2118
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (2037) 2037
middle aged (1511) 1511
cholesterol (1438) 1438
atorvastatin (1415) 1415
rats (1227) 1227
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (1132) 1132
aged (1061) 1061
pravastatin (1060) 1060
adult (1044) 1044
simvastatin - therapeutic use (1004) 1004
antilipemic agents (989) 989
mice (884) 884
hypercholesterolemia (772) 772
research (742) 742
anticholesteremic agents - pharmacology (698) 698
lipids (693) 693
lovastatin (668) 668
cells, cultured (662) 662
expression (662) 662
simvastatin - administration & dosage (657) 657
atherosclerosis (643) 643
dose-response relationship, drug (640) 640
analysis (639) 639
cardiac & cardiovascular systems (637) 637
hypercholesterolemia - drug therapy (609) 609
atorvastatin calcium (578) 578
inflammation (565) 565
risk (543) 543
statin (540) 540
cholesterol - blood (535) 535
coa reductase inhibitors (534) 534
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (528) 528
anticholesteremic agents - therapeutic use (526) 526
therapy (509) 509
apoptosis (505) 505
peripheral vascular disease (494) 494
drug interactions (492) 492
rats, sprague-dawley (491) 491
cholesterol, ldl - blood (490) 490
treatment outcome (490) 490
lovastatin - pharmacology (486) 486
in-vitro (478) 478
biochemistry & molecular biology (475) 475
risk factors (470) 470
disease models, animal (449) 449
heptanoic acids - pharmacology (448) 448
prevention (445) 445
metabolism (444) 444
drug therapy (441) 441
pyrroles - pharmacology (440) 440
coronary-heart-disease (433) 433
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (419) 419
time factors (413) 413
oxidative stress (407) 407
rats, wistar (407) 407
drugs (404) 404
lovastatin - analogs & derivatives (404) 404
hmg-coa reductase (401) 401
medicine & public health (399) 399
medicine, research & experimental (399) 399
drug therapy, combination (397) 397
disease (396) 396
dosage and administration (395) 395
rosuvastatin (395) 395
pharmacology (390) 390
nitric-oxide synthase (385) 385
health aspects (378) 378
care and treatment (377) 377
ezetimibe (377) 377
pharmacokinetics (368) 368
lipids - blood (367) 367
cell biology (360) 360
pravastatin - pharmacology (359) 359
inhibition (358) 358
efficacy (348) 348
cardiovascular diseases (330) 330
pharmacology/toxicology (323) 323
physiological aspects (320) 320
cells (318) 318
safety (314) 314
triglycerides - blood (313) 313
activation (311) 311
double-blind method (307) 307
apoptosis - drug effects (304) 304
proteins (300) 300
medicine (299) 299
simvastatin - adverse effects (298) 298
low density lipoproteins (292) 292
enzymes (291) 291
heptanoic acids - therapeutic use (289) 289
cell line, tumor (288) 288
hydroxymethylglutaryl-coa reductase inhibitors (287) 287
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8097) 8097
Chinese (83) 83
Japanese (76) 76
French (24) 24
Russian (22) 22
Spanish (17) 17
German (11) 11
Italian (9) 9
Polish (8) 8
Portuguese (8) 8
Dutch (4) 4
Hungarian (4) 4
Arabic (1) 1
Croatian (1) 1
Danish (1) 1
Finnish (1) 1
Hebrew (1) 1
Slovenian (1) 1
Swedish (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drug metabolism and disposition, ISSN 1521-009X, 2007, Volume 35, Issue 8, pp. 1308 - 1314
Hepatic uptake carriers of the organic anion-transporting peptide (OATP) family of solute carriers are more and more recognized as being involved in hepatic... 
RAT | SEVERE RHABDOMYOLYSIS | COMBINATION THERAPY | LIVER | PHARMACOLOGY & PHARMACY | CERIVASTATIN | HEPATIC-UPTAKE | TRANSPLANT RECIPIENTS | ROSUVASTATIN | POLYPEPTIDE | FAMILY | Organic Anion Transporters, Sodium-Independent - genetics | Fatty Acids, Monounsaturated - pharmacology | Cricetulus | Hypolipidemic Agents - metabolism | Hypoglycemic Agents - metabolism | Taurocholic Acid - metabolism | Humans | Hepatocytes - metabolism | Simvastatin - pharmacology | Organic Anion Transporters - metabolism | Chromans - metabolism | Hepatocytes - cytology | Indoles - metabolism | Organic Anion Transporters - genetics | Drug Interactions | Anticholesteremic Agents - metabolism | Chromans - pharmacology | Fatty Acids, Monounsaturated - metabolism | Organic Anion Transporters, Sodium-Independent - metabolism | Indoles - pharmacology | Biological Transport - drug effects | Thiazolidinediones - pharmacology | Hepatocytes - drug effects | Solute Carrier Organic Anion Transporter Family Member 1B3 | CHO Cells | Pravastatin - pharmacology | Recombinant Proteins - metabolism | Taurocholic Acid - pharmacology | Cell Line | Cricetinae | Pravastatin - metabolism | Simvastatin - metabolism | Gemfibrozil - pharmacokinetics | Gemfibrozil - pharmacology | Hypolipidemic Agents - pharmacology | Thiazolidinediones - metabolism | Hypoglycemic Agents - pharmacology | Animals | Estrone - analogs & derivatives | Estrone - metabolism | Protein Binding | Fatty Acids, Monounsaturated - pharmacokinetics | Indoles - pharmacokinetics | Kinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Anticholesteremic Agents - pharmacology | Gemfibrozil - metabolism
Journal Article
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 08/2004, Volume 24, Issue 8, pp. 1454 - 1459
OBJECTIVE—Neural apoptosis-regulated convertase (NARC)-1 is the newest member of the proprotein convertase family implicated in the cleavage of a variety of... 
HepG2 | QPCR | Primary hepatocytes | Cholesterol | SRE | CELLS | ELEMENT-BINDING PROTEIN-2 | primary hepatocytes | AUTOSOMAL-DOMINANT HYPERCHOLESTEROLEMIA | LOW-DENSITY-LIPOPROTEIN | NUCLEAR RECEPTOR LXR | TARGET GENES | PATHWAY | LIVER | cholesterol | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | EXPRESSION | Consensus Sequence | Lovastatin - pharmacology | Species Specificity | Humans | Regulatory Sequences, Nucleic Acid | Homeostasis | Lovastatin - analogs & derivatives | Hepatocytes - metabolism | Simvastatin - pharmacology | Promoter Regions, Genetic - genetics | Quinolines - pharmacology | RNA, Messenger - biosynthesis | Cell Line - drug effects | Base Sequence | Liver X Receptors | Serine Endopeptidases - genetics | Orphan Nuclear Receptors | Proprotein Convertases | Sp1 Transcription Factor - physiology | Hepatocytes - drug effects | Heptanoic Acids - pharmacology | Tretinoin - pharmacology | Mevalonic Acid - pharmacology | Cell Line - metabolism | DNA-Binding Proteins - physiology | Transcription Factors - physiology | Serine Endopeptidases - biosynthesis | Receptors, Cytoplasmic and Nuclear - drug effects | Rats | Hydroxymethylglutaryl CoA Reductases - physiology | Reverse Transcriptase Polymerase Chain Reaction | Hydroxycholesterols - pharmacology | Sequence Homology, Nucleic Acid | Gene Expression Regulation - drug effects | Mevalonic Acid - analogs & derivatives | Atorvastatin Calcium | Pyrroles - pharmacology | Sequence Alignment | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Cholesterol - pharmacology | Mice | Pyridines - pharmacology | Cholesterol - biosynthesis | Sterol Regulatory Element Binding Protein 2 | Proprotein Convertase 9
Journal Article
Journal of cellular and molecular medicine, ISSN 1582-1838, 2018, Volume 22, Issue 12, pp. 6122 - 6133
Interleukin (IL)‐33 is a member of the IL‐1 family and is able to act cardioprotective. The aim of this study was to investigate the regulation of IL‐33 by... 
cardiac cells | interleukin‐33 | bisphosphonates | pleiotropic | statins | interleukin-33 | MYOCYTES IN-VITRO | MEDICINE, RESEARCH & EXPERIMENTAL | CHRONIC HEART-FAILURE | CONTROLLED-TRIAL | NECROSIS-FACTOR-ALPHA | IL-33 | HUMAN ENDOTHELIAL-CELLS | ACTIVATOR INHIBITOR-1 EXPRESSION | CELL BIOLOGY | HYPERTROPHY | GROWTH-FACTOR-BETA | TNF-ALPHA | Lovastatin - pharmacology | Apoptosis - drug effects | Humans | Simvastatin - pharmacology | Fluvastatin - pharmacology | Monoterpenes - pharmacology | Heart Diseases - diet therapy | Myocardium - metabolism | Thiazolidines - pharmacology | Cytokines - genetics | Amides - pharmacology | Mevalonic Acid - pharmacology | Pravastatin - pharmacology | Myocardium - pathology | rhoA GTP-Binding Protein | Gene Expression Regulation - drug effects | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Interleukin-33 - genetics | Myocytes, Cardiac - drug effects | Fibroblasts - drug effects | 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid - pharmacology | Cyclohexenes - pharmacology | Heart - drug effects | Myocytes, Cardiac - metabolism | Heart Diseases - drug therapy | Pyridines - pharmacology | Diphosphonates - pharmacology | Interleukins | Statins | Cardiovascular agents | Heart | Interleukin | Lovastatin | mRNA | Myocytes | Pravastatin | Kinases | Bisphosphonates | Proteins | Lipophilic | Alendronic acid | Mevalonic acid | Fluvastatin | Fibroblasts | Cytokines | Simvastatin | RhoA protein | Cardiomyocytes | Ibandronic acid | Patients | Inhibitors | latrunculin B | Atorvastatin | Reductase | Original
Journal Article
American Journal of Physiology - Cell Physiology, ISSN 0363-6143, 05/2011, Volume 300, Issue 5, pp. 1181 - 1192
Enhanced vascular arginase activity impairs endothelium-dependent vasorelaxation by decreasing l-arginine availability to endothelial nitric oxide (NO)... 
Endothelial nitric oxide synthase dysfunction | PHYSIOLOGY | BLOOD-PRESSURE | P38 MAP KINASE | CELL BIOLOGY | INCREASED ARGINASE ACTIVITY | NITRIC-OXIDE PRODUCTION | INHIBITION | MOUSE MODEL | endothelial nitric oxide synthase dysfunction | CARDIOVASCULAR-DISEASE | SMOOTH-MUSCLE-CELLS | HYPERTENSIVE-RATS | CONTRIBUTES | Phosphorylation | Endothelial Cells | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - analogs & derivatives | Endothelium, Vascular - drug effects | Endothelium, Vascular - enzymology | GTP-Binding Protein alpha Subunits, G12-G13 - antagonists & inhibitors | Simvastatin - pharmacology | Angiotensin II Type 1 Receptor Blockers - pharmacology | rho-Associated Kinases - antagonists & inhibitors | Cattle | Arginase - antagonists & inhibitors | Amides - pharmacology | Cell Line | rho-Associated Kinases - physiology | Angiotensin II - pharmacology | p38 Mitogen-Activated Protein Kinases - physiology | RNA, Small Interfering - pharmacology | Endothelium, Vascular - physiopathology | Enzyme Inhibitors - pharmacology | GTP-Binding Protein alpha Subunits, Gq-G11 - antagonists & inhibitors | Imidazoles - pharmacology | Animals | Signal Transduction - drug effects | 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacology | p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors | Signal Transduction - physiology | Mice | Pyridines - pharmacology | Arginase - physiology | Angiotensin II - physiology | Boronic Acids - pharmacology | Abnormalities | Angiotensin | Physiological aspects | Vascular endothelium | Genetic aspects | Research | Mitogen-activated protein kinases | Index Medicus | Vascular Biology
Journal Article
Xenobiotica, ISSN 0049-8254, 6/2013, Volume 43, Issue 6, pp. 498 - 508
1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and... 
P-glycoprotein | BCRP | transporters | Cytochrome P450 | OATP | dyslipidemia | diabetes | pharmacogenetics | Pharmacogenetics | Dyslipidemia | Transporters | Diabetes | POLYMORPHISM MARKEDLY AFFECTS | SLCO1B1 POLYMORPHISM | ATORVASTATIN | INHIBITION | PHARMACOKINETICS | FLUVASTATIN | PHARMACOLOGY & PHARMACY | TOXICOLOGY | SIMVASTATIN | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Simvastatin - adverse effects | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Male | Heptanoic Acids - adverse effects | Simvastatin - pharmacology | Fluorobenzenes - pharmacology | Young Adult | Drug Interactions | Piperidines - pharmacology | Oxadiazoles - pharmacology | Madin Darby Canine Kidney Cells | Pyrroles - adverse effects | Oxadiazoles - pharmacokinetics | Heptanoic Acids - pharmacology | Mesylates - blood | Troleandomycin - adverse effects | Rosuvastatin Calcium | Mesylates - adverse effects | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Simvastatin - analogs & derivatives | Sulfonamides - pharmacokinetics | Oxadiazoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Cytochrome P-450 CYP3A - metabolism | Adolescent | Atorvastatin | Pyrimidines - pharmacokinetics | Oxadiazoles - blood | Demography | Heptanoic Acids - pharmacokinetics | Mesylates - pharmacokinetics | Simvastatin - blood | Piperidines - blood | Troleandomycin - pharmacokinetics | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Reference Standards | Adult | Female | Piperidines - pharmacokinetics | Troleandomycin - pharmacology | Fluorobenzenes - blood | Pyrroles - blood | Simvastatin - pharmacokinetics | Pyrroles - pharmacology | Animals | Cytochrome P-450 CYP3A Inhibitors | Mesylates - pharmacology | Piperidines - adverse effects | Dogs | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Heptanoic Acids - blood
Journal Article
Journal Article
Journal of Endodontics, ISSN 0099-2399, 2012, Volume 38, Issue 3, pp. 405 - 410
Abstract Introduction We previously reported that bismuth oxide containing Portland cement (BPC) showed similar biocompatibility to Portland cement (PC) in... 
Endocrinology & Metabolism | Dentistry | human dental pulp cells | differentiation | Bismuth oxide | simvastatin | growth | Emdogain | Portland cement | STEM-CELLS | HUMAN TEETH | OSTEOBLAST DIFFERENTIATION | PROLIFERATION | MINERAL TRIOXIDE AGGREGATE | IN-VITRO | INHIBITION | BONE-FORMATION | DENTISTRY, ORAL SURGERY & MEDICINE | HEME OXYGENASE-1 | END FILLING MATERIAL | Coloring Agents | Humans | Dental Cements - pharmacology | Core Binding Factor Alpha 1 Subunit - analysis | Simvastatin - pharmacology | Tetrazolium Salts | Thiazoles | Alkaline Phosphatase - analysis | Cell Culture Techniques | Pulp Capping and Pulpectomy Agents - pharmacology | Osteocalcin - analysis | Calcium Compounds - pharmacology | Silicates - pharmacology | Cell Line | Cell Survival - drug effects | Calcification, Physiologic - drug effects | Odontogenesis - drug effects | Dental Pulp - cytology | Dental Pulp - drug effects | Materials Testing | Biocompatible Materials - pharmacology | Dental Enamel Proteins - pharmacology | Reverse Transcriptase Polymerase Chain Reaction | Oxides - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Anthraquinones | Cell Differentiation - drug effects | Odontoblasts - drug effects | Sp7 Transcription Factor | Bismuth - pharmacology | Aluminum Compounds - pharmacology | Cell Proliferation - drug effects | Transcription Factors - analysis | Osteopontin - analysis | Drug Combinations | Bismuth | Analysis | Simvastatin | Cells | Cement
Journal Article
Journal Article
Scientific Reports, ISSN 2045-2322, 11/2015, Volume 5, Issue 1, p. 17047
Journal Article